Aadi Bioscience appoints Brendan Delaney as COO
Most recently Mr. Delaney was Chief Commercial Officer at Constellation Pharmaceuticals.
Mr. Delaney began his career at Bristol-Myers, Genentech and Chiron in roles of increasing responsibility in oncology marketing and strategy, and led global branding, strategy and franchises in Novartis’ oncology division for blockbuster brands.
At Immunomedics, Mr. Delaney led the build-out of the marketing, sales, market access and commercial operations teams related to TRODELVY.
Prior to his Chief Commercial Officer roles at Constellation and Immunomedics, he was Vice President, U.S. Commercial Hematology Oncology of Celgene Corporation, prior to its acquisition by Bristol-Myers Squibb in 2019. ■